Search
Close this search box.

Science Spotlight: Cimeio’s cell-shielding technology, stopping EBV-driven cancer and more

ARTICLE | Discovery & Translation

BioCentury’s roundup of translational innovations

By Danielle Golovin, Senior Biopharma Analyst

May 29, 2024 11:58 PM UTC

Cimeio Therapeutics Inc., ADC Therapeutics S.A. (NYSE:ADCT) and collaborators at University of Basel selectively eradicated leukemic cells while preserving hematopoiesis by shielding healthy cells from an ADC targeting a pan-hematopoietic marker.

The Nature paper authors engineered a base edit in PTPRC that preserved hematopoietic stem and progenitor cell (HSPC) functions but shielded them from a PTPRC-targeting antibody-drug conjugate.